Newsletter

XBIT - Biotechnology-Cloning Anti-Ebola (Must Read!!!)

(Mailing list information, including unsubscription instructions, is located at the end of this message.)

XBiotech Inc. (XBIT)

Guinea and Sierra Leone have reported 35 new Ebola cases in the past week, four times as many as the week before, providing a reminder that the virus "will not go quietly", a top World Health Organization official said.

After the closing bell on Tuesday, XBIT reported that it has successfully isolated and cloned an anti-Ebola product candidate using its True Human antibody discovery platform

True Human antibodies are derived directly from human donors that have natural immunity to disease. According to XBIT, the anti-Ebola product candidate that could be used to treat the disease was developed from a blood donation received earlier this year from a patient who recovered from Ebola infection.

XBIT is pioneering a new era in the discovery and development of targeted antibodies based on its True Human(TM) technology.

More about XBiotech Inc. (XBIT) at www.xbiotech.com.

**

Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The Company has updated its business plan ( http://crownequityholdings.com/extras/Business_Plan.pdf )

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

General Disclaimer: Statements on this newsletter may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Crown Equity Holdings Inc. provides links to websites operated by third parties. These links may be of interest or of use to you, and are provided for convenience only. You should be aware that in using these links, you are leaving Crown Equity Holdings Inc’s website. Crown Equity Holdings Inc. does not approve or endorse the content, information or materials available on such third party websites. In addition, Crown Equity Holdings Inc. makes no representation regarding, and is not responsible for, the content, information or material available on such websites. If you decide to access such websites or newsletter you do this at your own risk, and Crown Equity Holdings Inc. will not be liable for any loss or damage associated with your use of, or reliance on, the content, information or material available on such website. Read Full Disclaimer at   www.pennytobuck.com/disclaimer